COMMON INITIAL DOSING REGIMENS

• Clinical trials have utilized doses of 5–10 mg administered subcutaneously once daily. Cyclic administration protocols are sometimes used in research settings, such as four weeks on and two weeks off.

MECHANISM OF ACTION

• SS-31 selectively targets cardiolipin within the mitochondrial inner membrane. By binding to cardiolipin, it stabilizes the mitochondrial cristae structure, enhances electron transport efficiency, and reduces the production of reactive oxygen species (ROS). This supports mitochondrial function and decreases oxidative stress, which is critical in aging and degenerative diseases.

COMMON SIDE EFFECTS

• Mild: Injection site pain or redness, fatigue, and transient headache.

• Metabolic: Nausea or appetite changes.

• Rare: Theoretical risks include mitochondrial overactivation leading to cellular stress or dysregulated energy production.

CONTRAINDICATIONS

• Absolute: Hypersensitivity to Elamipretide or its components.

• Relative: Patients with mitochondrial disorders or severe systemic illnesses should use it cautiously due to limited human safety data.

DISCLAIMER

• This medication is experimental and not FDA-approved.

MORE INFORMATION

• FDA Safety Data Sheet not available (experimental peptide).